Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cu-medicine-developed-an-innovative-mrna-drug-for-treatment-of-nasopharyngeal-carcinoma
https://www.med.cuhk.edu.hk/press-releases/cu-medicine-developed-an-innovative-mrna-drug-for-treatment-of-nasopharyngeal-carcinoma

CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

mRNA study for NPC

CU Medicine collaborated with The Jackson Laboratory in the US to develop an innovative mRNA drug for treatment of nasopharyngeal carcinoma (NPC) targeting (Epstein-Barr virus) EBV-carrying cancer cells. Researchers observed promising outcomes in mouse model, suggesting that the novel drug can work in synergy with immunotherapy and serve as a treatment option for other EBV-associated cancer types.

Research team members include (2nd from left) Assistant Professor Anna Tsang Chi-man and Professor Lo Kwok-wai from the Department of Anatomical and Cellular Pathology at CU Medicine; Professor Brigette Ma Buig-yue from the Department of Clinical Oncology at CU Medicine; Dr Albert Wu Cheng from The Jackson Laboratory; and Dr Li Lixian, Associate Professor from the Department of Surgery at CU Medicine.

Nasopharyngeal carcinoma (NPC) is a cancer type strongly associated with Epstein-Barr virus (EBV) infection. The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) saw the potential of EBV as a therapeutic target and successfully developed an innovative mRNA drug for treatment of NPC targeting EBV-carrying cancer cells. Researchers observed promising outcomes in mouse model, suggesting that the novel drug can work in synergy with immunotherapy and serve as a treatment option for other EBV-associated cancer types. The findings were recently published in Nature Communications.

 

EBV as a tumour therapeutic target

 

Professor Ma

Professor Brigette Ma says the stage of NPC is an important prognostic factor influencing survival. The overall 5-year relative survival drops from over 90% at early stage to less than 50% at advanced stage.

NPC, known as “Canton tumour” due to its high prevalence in Southern China, is the most common head and neck cancer in Hong Kong. According to the data of the Hong Kong Cancer Registry in 2021, NPC ranked 9th among the most common cancer types in men and 10th in mortality, with over 550 registered new cases. Notably, NPC is the most common cancer in the 20 to 44 age group of Hong Kong males with over 110 cases.    

 

The stage of NPC is an important prognostic factor influencing survival. The overall 5-year relative survival drops from over 90% at early stage to less than 50% at advanced stage. However, treatment options for NPC patients with advance disease or recurrent and metastasis tumours are limited as targeted therapy for NPC-specific mutations is not yet available.

 

Professor Lo Kwok-wai, Professor in the Department of Anatomical and Cellular Pathology at CU Medicine, said, “CU Medicine has played an instrumental role in the study of NPC over the past two decades, unraveling the whole genome of NPC and proving plasma EBV DNA screening as an effective diagnostic tumour marker for the early detection of NPC. In this study, we further explored the potential of EBV as a tumour therapeutic target and successfully developed a novel drug by using mRNA technology.”   

The mRNA lipid nanoparticle induces detonation of EBV-positive cancer cells

 

Professor Anna Tsang

Professor Anna Tsang describes the new mRNA lipid nanoparticle as “smart bomb”. It acts like a switch to activate the lytic cycle of EBV in cancer cells and induces detonation.  

Researchers from the Department of Anatomical and Cellular Pathology at CU Medicine collaborated with  The Jackson Laboratory in the US to develop a synthetic mRNA drug to switch on an EBV-specific suicide mechanism to kill the NPC cancer cells. A lipid nanoparticle encapsulating nucleoside-modified mRNA which encodes an artificial transcriptional activator named mTZ3-LNP is synthesised for the mRNA-based EBV-targeted therapy. 

 

Professor Anna Tsang Chi-man, Assistant Professor in the Department of Anatomical and Cellular Pathology at CU Medicine, explained, “Once EBV enters our cells, the virus can remain in a latent state and stay inactive. Upon reactivation, the virus enters lytic cycle and its host cell dies along with this process.  The lipid nanoparticle we developed acts like a switch to activate the lytic cycle and induces detonation. From the study results, we showed the potency and safety of treatment with the activator to suppress tumour growth in EBV-positive cancer models.” 

Professor Lo Kwok wai

Professor Lo Kwok-wai says the mRNA drug they developed targets EBV-positive cancer cells. Fewer side effects are expected compared with chemotherapy which kills not only cancer cells.

Professor Lo added, “mRNA drugs have been tried out in therapy of several cancer types, including liver cancer. We pioneered the trial of mRNA technology in NPC treatment and were delighted to see promising results in mouse model, without resistance. Since the drug targets EBV-positive cancer cells, fewer side effects are expected compared with chemotherapy which doesn’t only kill cancer cells. We anticipate this novel EBV-targeted drug can work in synergy with immunotherapy for better treatment outcome. Other than NPC, the nanoparticle can also serve other EBV-associated cancer types.”

 

This study was funded by the Innovation and Technology Fund, Health and Medical Research Fund and Research Grant Council’s Areas of Excellence Scheme.

 

More Press Releases

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
 CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK develops a state-of-the-art computational model to accurately forecast viral genetic evolution and facilitate improvement of influenza vaccines’ protective effects

CUHK develops a state-of-the-art computational model to accurately forecast viral genetic evolution and facilitate improvement of influenza vaccines’ protective effects

Research
CU Medicine combats resistance to immunotherapy in liver cancer

CU Medicine combats resistance to immunotherapy in liver cancer

Research
CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

Research
CUHK discovers a blood regulator linked to tumour microenvironment formation,  sparking a new therapeutic target for lung cancer

CUHK discovers a blood regulator linked to tumour microenvironment formation, sparking a new therapeutic target for lung cancer

Research
CUHK study opens up a new treatment direction for autoimmune eye inflammation

CUHK study opens up a new treatment direction for autoimmune eye inflammation

Research
International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

Research
Professor Anthony Chan honoured with the ESMO Lifetime Achievement Award  Global recognition for his leadership and outstanding research in nasopharyngeal cancer

Professor Anthony Chan honoured with the ESMO Lifetime Achievement Award Global recognition for his leadership and outstanding research in nasopharyngeal cancer

Awards and honors
CUHK Phase 1 Clinical Trial Centre celebrates 10th anniversary Centre has completed 150 early-stage studies of novel drugs for cancer, diabetes and more

CUHK Phase 1 Clinical Trial Centre celebrates 10th anniversary Centre has completed 150 early-stage studies of novel drugs for cancer, diabetes and more

Research
CUHK study concludes that plasma EBV DNA screening can detect early asymptomatic nasopharyngeal cancer and reflect the risk of future cancer development

CUHK study concludes that plasma EBV DNA screening can detect early asymptomatic nasopharyngeal cancer and reflect the risk of future cancer development

Research
New algorithm can predict diabetic kidney disease A simple blood sample could help doctors catch kidney disease earlier in type 2 diabetes patients

New algorithm can predict diabetic kidney disease A simple blood sample could help doctors catch kidney disease earlier in type 2 diabetes patients

Research
International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Research
CUHK unlocks the secret of cancer pain  Identifying a new therapeutic key to ending the sorrow

CUHK unlocks the secret of cancer pain Identifying a new therapeutic key to ending the sorrow

Research
CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

Research
Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Education
CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
A Joint Study by CUHK, PolyU and Western Sydney University Discovers how the Nervous System of Human Runners Generates More Energetically Efficient Running Forms

A Joint Study by CUHK, PolyU and Western Sydney University Discovers how the Nervous System of Human Runners Generates More Energetically Efficient Running Forms

Research
CUHK Study Discovers Brain Circuitry That Generates Behavioural Responses to Stress Provide a Basis for Probing Abnormal Repetitive Behaviour Exhibited in Brain Disorders

CUHK Study Discovers Brain Circuitry That Generates Behavioural Responses to Stress Provide a Basis for Probing Abnormal Repetitive Behaviour Exhibited in Brain Disorders

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK’s Gerald Choa Neuroscience Centre Unveils Mystery of How Brain Learns Motor Skills

CUHK’s Gerald Choa Neuroscience Centre Unveils Mystery of How Brain Learns Motor Skills

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
CUHK Opens Phase I Clinical Trial Centre To Step Up New Drug Development in Hong Kong

CUHK Opens Phase I Clinical Trial Centre To Step Up New Drug Development in Hong Kong

Research
CUHK Launches Territory-wide Screening Study for Early Detection of Nasopharynx Cancer Now Recruiting 20,000 Citizens to Join

CUHK Launches Territory-wide Screening Study for Early Detection of Nasopharynx Cancer Now Recruiting 20,000 Citizens to Join

Research
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.